Background. Although a number of risk factors have been associated with invasive fungal disease (IFD), a systematic review of the literature to document pediatric-specific factors has not been performed.
Children with cancer or those who undergo hematopoietic stem cell transplantation (HSCT) [1] [2] [3] are at risk for invasive fungal disease (IFD), and IFDs are an important contributor to morbidity and mortality. The systematic identification of risk factors for IFD is a necessary step in stratifying patients into a high-or low-risk group. This risk stratification then can serve as the foundation for the development of efficient supportive care guidelines that will inform clinical decisions relevant to the management of IFD, such as when to perform fungal diagnostic testing and when to initiate empiric antifungal therapy.
The authors of several narrative reviews described risk factors for IFD [4, 5] . A systematic review is a more methodologically rigorous approach, because it ensures that all eligible studies are included, their methods are assessed, and the published data are used comprehensively to inform IFD risk designation. Such efforts are now ubiquitous throughout medicine, including the development of a risk-prediction rule for microbiologically documented infection in pediatric fever and neutropenia [6] . However, to our knowledge, no such comprehensive effort to identify factors associated with IFD in pediatric cancer and HSCT recipients has been conducted.
The objective of this systematic review was to identify risk factors for IFD in children with cancer or HSCT patients. These risk factors can then be used to inform high and low risk stratification for IFD in this patient population.
METHODS
For this systematic review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for reporting [7] .
Briefly, PRISMA is a methodology developed to assist researchers in performing systematic reviews and meta-analyses. Among other things, PRISMA provides guidance to authors on developing an a priori plan for a systematic review and includes a checklist of items to be included in the study protocol. The overarching goal of PRISMA is to improve the conduct and quality of published systematic reviews by standardizing practice.
Data Sources and Searches
We used the Ovid SP platform to search Medline, Medline In-Process, and Embase for articles indexed up to March 14, 2016 . The search strategy included Medical Subject Heading terms and text words aimed to identify publications that describe factors associated with IFD in children and adolescents (<25 years old) with cancer or those who undergo HSCT. The full search strategy is shown in Supplementary Appendix 1. The set was limited to studies published in 1980 or more recently. There was no restriction according to language.
Study Selection
Eligibility criteria were established a priori. A study was included if (1) the subjects were children or adolescents with cancer or were undergoing HSCT, (2) it was a fully published primary study, and (3) the number of patients with IFD and factors associated with IFD were described in the study report. Studies were excluded if (1) the report was not a full-text publication, (2) patients aged 25 years or older were included, (3) less than 90% of the patients had cancer or were HSCT recipients, (4) the number of patients with IFD was not described, (5) no control group was used or the risk of IFD between patients with and those without a risk factor of interest were not compared, (6) fewer than 10 patients with IFD were evaluated, (7) Pneumocystis jirovecii was the only fungal pathogen examined, or (8) it was only an assessment of the effectiveness of prophylactic antifungal therapy.
Two reviewers (P. D. R. and L. S.) independently evaluated the titles and abstracts of publications identified by the search strategy, and all potentially relevant publications were retrieved in full. These same 2 reviewers evaluated full-text articles to decide whether our eligibility criteria were met. Final inclusion of a study into the systematic review was decided by agreement between both reviewers. We described agreement regarding study inclusion using the κ statistic; agreement was defined as slight (0%-20%), fair (21%-40%), moderate (41%-60%), substantial (61%-80%), or almost perfect (81%-100%) [8] .
Data Abstraction and Methodological Approach
Two reviewers (P. D. R. and L. S.) abstracted all data from the publications in duplicate, and any discrepancies were resolved by consensus. The primary variables of interest were risk factors for IFD, including underlying diagnosis, treatment including steroids, neutropenia, and other factors. Results of multiple regression or other adjusted analyses were displayed preferentially. Studies were stratified according to those in which the researchers evaluated for IFD risk throughout the duration of a chemotherapy treatment period or after HSCT versus those who evaluated IFD risk specifically during periods of fever and neutropenia.
Study attributes abstracted included years of study publication and enrollment, patient age range, patient population (cancer, HSCT, or both) and specific population details, and study design. We also recorded the setting in which IFD risk was evaluated (eg, during treatment, after HSCT, during fever and neutropenia), antifungal prophylaxis, whether IFD was defined using the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) consensus criteria, the definition of cases, and how possible IFDs were handled. Last, we abstracted statistically significant risk factors. If both univariate and multiple regression analyses were conducted, only multiple regression (if a sufficient number of events were evaluated) was shown. Meta-analysis was not planned, because excessive heterogeneity was expected, and a narrative approach to synthesizing the data was undertaken.
Assessment of Study Quality
Two reviewers (P. D. R. and L. S.) assessed study quality, and discrepancies were resolved by consensus. Study quality was evaluated using a modified version of an instrument previously developed to describe quality in studies of prognosis [9] . This quality-assessment instrument examines 4 potential sources of bias: study participation, study attrition, confounding variables, and measurement of outcomes. Relevant to this systematic review, we abstracted data on bias related to study participation, confounding variables, and measurement of outcomes; they were rated as having a low, high, or uncertain risk of bias [9] . Figure 1 shows the flow of study publication identification and selection. We found 3566 unique citations identified by the search strategy, of which, 51 were retrieved for full-text evaluation. Among these publications, 22 met the eligibility criteria and were included in the systematic review (Table 1) . Reasons for exclusion are listed in Figure 1 . Agreement in study inclusion between the 2 reviewers was perfect (κ = 100%).
RESULTS
In terms of patient population enrolled, 8 studies [10-17] enrolled only patients undergoing HSCT, and 6 of those studies enrolled only patients undergoing allogeneic HSCT. There were 10 studies that exclusively enrolled patients with cancer [1, [18] [19] [20] [21] [22] [23] [24] [25] [26] , although some of these patients might have undergone HSCT after enrollment. Both patients with cancer and HSCT recipients were included in 4 studies [27] [28] [29] [30] . Among the 22 studies, 18 (82%) assessed IFD risk throughout the duration of the chemotherapy treatment period or post-HSCT period [1, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [27] [28] [29] , and the remaining 4 (18%) assessed IFD risk only during fever and neutropenia [24] [25] [26] 30] . Fourteen (64%) studies used the EORTC/MSG criteria to classify cases of IFD [31] .
Across the identified studies, we evaluated a variety of potential risk factors for IFD, including underlying diagnosis, age, graft-versus-host disease (GVHD), neutropenia, and immunosuppressive agents such as chemotherapy, corticosteroids, and HSCT conditioning regimens. Various diagnoses were statistically significantly associated with IFD (Table 2) . Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) [22, 29] portended an increased risk for IFD relative to other cancer diagnoses, whereas AML was associated with a greater risk for IFD than ALL [21, 26] . Among HSCT recipients, both severe aplastic anemia and Fanconi anemia as the indication for transplant were associated with increased risk for IFD [15] . Neutropenia, defined in various ways (eg, an absolute neutrophil count [ANC] less than 100 cells/μL or duration of neutropenia more than 28 days), was found to be associated with IFD in 6 studies; 3 of those studies were in children with leukemia, 2 were HSCT cohorts, and 1 included both HSCT recipients and patients with cancer. Among patients with leukemia, neutropenia at the start of chemotherapy [1] or a decline in the ANC to less than 100 cells/μL [23] were each associated with increased risk of IFD. In HSCT cohorts, the duration of neutropenia in days [17] , as a continuous variable, was found to increase the risk for IFD, and neutropenia duration dichotomized at a threshold of more than 28 days [15] was significantly associated with IFD.
Certain corticosteroid exposures, chemotherapy courses, and conditioning regimens were associated with increased risk for IFD. Exposure to high-dose corticosteroids was correlated with an increased risk for IFD in 3 separate HSCT cohorts [11, 
15, 17]
, and the duration of steroid exposure was associated with IFD in 1 cohort of patients with AML [1] and in a second study inclusive of HSCT recipients and patients with cancer [30] . Chemotherapy regimens associated with an increased risk for IFD included intensive-induction timing versus standard timing associated with AML protocol CCG2891 [20] and relapse versus front-line therapy in children with AML [19] , whereas reduced-intensity conditioning was associated with an increased risk of IFD in allogeneic HSCT recipients [13] .
GVHD was commonly identified as a risk factor for IFD; 4 HSCT studies found a significant association with severe acute GVHD [10, 12, 17, 29] , and 3 studies associated IFD with chronic GVHD [12, 14, 17, 29] . In these studies, severe GVHD was inclusive of grade II and higher [10, 17, 29] or grade III and higher [12] . Last, increasing age was identified as a risk factor for IFD in both HSCT recipients and patients with cancer. Age was dichotomized at a threshold of 7.5 and 10 years in 1 [13] and 5 [11, 14, 15, 18, 20] studies, respectively. In each of these studies, the older age group had an increased risk for IFD.
In the studies that focused on episodes of fever and neutropenia, significant risk factors for IFD were fever on day 4 of neutropenia, an acute monocyte count of <100/ μL on day 4, a C-reactive protein level greater than or equal to 9.0 mg/dL on day 4 of neutropenia after fever onset [24] [25] [26] 30] . 
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DISCUSSION
In this systematic review, we identified 22 studies that investigated risk factors for IFD in at-risk pediatric patients. These studies were heterogeneous relative to the patient populations studied and included HSCT recipients and children with cancer. The studies also focused on risk at different clinical time points and assessed various potential risk factors with various methods of measurement for each factor. This heterogeneity prohibited an analysis that would combine data across studies. Nonetheless, the results of this systematic review confirm a number of risk factors often associated with IFD and provide a more granular understanding of these risk factors. Additional factors not typically associated with IFD risk, such as age, were also identified. As might be expected, neutropenia duration was the most commonly identified risk factor for IFD. Some of the analyses considered neutropenia as a continuous variable and, as such, revealed that each day of increased neutropenia duration had a corresponding increased risk for IFD. Thresholds for 28 and 30 days of neutropenia were associated with increased risk for IFD in 2 different studies. However, these thresholds seem to have been chosen arbitrarily for analyses, and it is not clear if such risk would have been present at lower thresholds [15, 30] . Johnston et al. [1] examined 2 different thresholds for neutropenia, 10 and 15 days. The 10-day threshold was not statistically significantly associated with IFD, but the 15-day threshold was. These data suggest that the risk for IFD from neutropenia in children significantly increases at some point beyond 10 days' duration, although the threshold likely also varies depending on other concurrent risk factors. Similarly, the published clinical practice guideline for adults with neutropenia denotes high-risk IFD status after 10 to 15 days of neutropenia [32] on the basis of published adult data that link an increased risk of invasive aspergillosis to neutropenia durations of at least 10 to 15 days [33] . It is important to note that lymphopenia was not assessed as a risk factor for IFD in the pediatric studies included in this systematic review. Lymphopenia has been identified as a risk factor for IFD in adult HSCT recipients [34] . Investigation of the impact of lymphopenia on the risk of IFD in children is needed.
The depth of neutropenia is also an important component of the neutropenia risk profile for IFD. An ANC of <100 μL before IFD onset, and specifically an acute monocyte count of <100 μL during an episode of fever and neutropenia, were each associated with an increased risk for IFD. Because both depth and duration of neutropenia were identified separately as a risk factor for IFD, it is intriguing to consider a single measure that would consider these elements simultaneously. The D-index is a measure that combines both depth and duration of neutropenia in a single assessment and has been linked to an increased risk for IFD [35] . However, this measure was derived only in a small case-control study and was not investigated in any of the studies included in this systematic analysis. Investigation of the D-index as a mechanism for stratifying patients according to risk of IFD should be considered.
High-dose steroid exposure was frequently identified as an independent risk factor for IFD in HSCT recipients and in patients with cancer. However, it should be noted that each study defined the threshold for high-dose steroid exposure in various ways, including 1 mg/kg per day of prednisolone for more than 1 week [11] , 2 mg/kg per day of prednisolone for 10 or more days [15] , 0.25 to 1 g/day of methylprednisolone for 5 days followed by 2 mg/kg per day of prednisolone [17] , and 10 mg/m 2 of dexamethasone [1] . This variation precludes us from defining a single dosing regimen for labeling someone as having received high-dose steroids.
A number of baseline clinical factors, such as a diagnosis of AML, high-risk or relapsed ALL, and allogeneic HSCT, were confirmed as risk factors for IFD. In addition, the children undergoing HSCT for severe aplastic anemia or Fanconi anemia had an increased risk for IFD [15] . As expected, intensive-timing versus standard-timing chemotherapy for AML [20] was associated with an increased IFD risk, but it was surprising to find that reduced-intensity conditioning for HSCT conferred an increased risk for IFD [13] . This increased risk with reduced-intensity conditioning was found only in 1 study and needs further investigation to confirm these findings. Finally, both severe acute and chronic GVHD were associated with IFD risk across a number of studies [10, 12, 14, 17, 29] . Age was the only demographic factor implicated in IFD risk across multiple studies. Increasing age correlated with increased IFD risk. Identified age thresholds for IFD risk included 7.5 [13] and 10 [11, 14, 15, 18, 20] . However, it is unclear if an association with IFD would have been identified at a lower age threshold. Age is not frequently a metric used for defining risk for IFD in children, but these data suggest that age should be considered in risk stratification. It is not clear whether age itself is a risk factor or rather a proxy for other factors, such as chemotherapeutic or conditioning treatment intensity, altered pharmacokinetics, or obesity or associated comorbidities such as hyperglycemia.
Although we were successful in identifying individual risk factors for IFD, we found a notable absence of any published prediction rules that leverage multiple factors simultaneously or in sequence to stratify patients into risk categories. The development of prediction rules has been successful for risk stratification regarding bacterial infections [36] [37] [38] [39] . Similar prediction rules for IFD would be clinically useful to inform targeted prophylactic and empiric antifungal therapy strategies. In the interim, we can use only the single risk factors to help guide IFD risk-stratification measures in clinical practice guidelines.
The primary strength of this review is its rigorous and systematic approach to identifying, screening, and including publications of all languages to ensure that all available published studies informed the identification of risk factors for IFD in children with cancer or those undergoing HSCT. Such a study had not been performed for this patient population despite the importance of establishing a systematic platform for pediatric IFD risk stratification that can be used to inform clinical management strategies. However, this review must be interpreted in light of its limitations. First, the outcome of IFD in this systematic review was inclusive of a heterogeneous group of fungal pathogens presenting across heterogeneous patient populations. Certain risk factors might be more or less important depending on the clinical scenario (ie, HSCT or leukemia) and depending on the pathogen of concern (ie, Candida species or invasive mold). However, the primary goal of this endeavor was to systematically identify risk factors that pediatric clinicians can leverage as general guides to increase or decrease their suspicion of IFD when caring for pediatric HSCT recipients and patients with cancer. Second, publication bias is difficult to test in this setting; thus, it is unknown if or how many negative studies were performed but not published. Third, risk for bias was assessed in each included study relative to patient selection, confounding, and analytic plan ( Table 2 ). In a number of studies the risk of bias for 1 or more of these parameters was high, which needs to be considered when assessing whether an identified factor or factors are truly associated with an increased risk for IFD. For example, the risk of bias related to confounding was high in 3 of the studies that found a significant association between acute GVHD and IFD (Table 2) , which suggests that it might not be an independent association. Last, we considered only risk factors that were shown to be statistically significantly associated with IFD in the studied population. This approach does not take into account the study's power, so there is an opportunity to identify spurious associations or missing clinically meaningful associations. Some of the risk factors were identified in univariate analysis without consideration for confounding by, or collinearity with, other covariates.
In conclusion, this systematic review summarizes individual risk factors identified in publications since 1980. In many instances, our results confirm factors that are routinely considered in daily clinical practice. Children undergoing allogeneic HSCT and those receiving chemotherapy for AML and high risk or relapsed ALL should be considered at high risk for IFD. Among these groups, patients with preceding Fanconi anemia or severe aplastic anemia who undergo HSCT and patients with AML who receive intensive therapy are at particularly increased risk. In addition, patients with neutropenia longer than 10 days and those receiving high-dose corticosteroids should be considered at high risk for IFD. Other factors, such as increasing age, are not routinely included in pediatric risk assessment but should be considered. Future efforts should focus on defining more precisely thresholds for particular risk factors (ie, age, neutropenia duration) and on development of prediction rules inclusive of individual factors to further refine risk prediction.
Additional investigation of other potential predisposing factors, such as genetic variation, is needed in large pediatric cohorts with well-defined measurement of IFD.
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